自新冠疫情以来,厦门宝太生物科技股份有限公司高度关注SARS-CoV-2在全球范围内出现的突变,并与厦门大学张永有教授紧密合作,持续跟踪分析SARS-CoV-2突变,以确保宝太新冠抗原试剂有效检出出现的突变毒株。我们积极跟踪WHO、GISAID、UK等报告的SARS-CoV-2突变株,利用相应的重组N蛋白对宝太生产的新冠抗原检测试剂进行了评估和验证。结果显示本公司生产的新冠抗原检测试剂可以有效检出阿尔法(Alpha, B.1.1.7),贝塔(Beta, B.1.351),德尔塔(Delta, B.1.617.2),奥密克戎(Omicron, B.1.1.529)。
Since the outbreak of COVID-19, Xiamen Biotime Biotechnology Co., Ltd. has paid high attention to the mutations of SARS-CoV-2 around the world, and closely cooperated with Professor Zhang Yongyou of Xiamen University to keep tracking and analyzing the mutations of SARS-CoV-2, ensuring that the novel coronavirus antigen kits produced by Biotime can effectively detect the present mutant strains. We actively followed up the SARS-CoV-2 mutant strains reported by WHO, GISAID and UK, and evaluated and verified the novel coronavirus antigen test kits produced by Biotime with corresponding recombinant N proteins. The results showed that the novel coronavirus antigen test kits produced by our company could efficiently detect Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529).
Omicron (B.1.1.529)两端测序结果
Sequence from both sides
Omicron (B.1.1.529)实验室测结果
Wet lab test result
© 2016 厦门宝太生物科技股份有限公司 版权所有闽ICP备2023000610号-1闽ICP备2023000610号-2